WuXi AppTec (2359) Stock Price, Fundamentals & Analysis

What 2359 does

WuXi AppTec (2359) is an investment holding company that provides research and manufacturing services for small-molecule drugs across China, the United States, Europe, and other international markets. It operates through four segments — WuXi Chemistry, WuXi Testing, WuXi Biology, and Others — offering end-to-end contract research, development, and manufacturing organization (CDRMO) services that span from early discovery through commercial production. Its capabilities cover small molecules, oligonucleotides, peptides, and complex conjugates, alongside biology services, laboratory testing (toxicology, DMPK, bioanalysis), and clinical contract research organization services from Phase I to Phase IV.

Key numbers explained

• 209.6 HKD is the current share price on the Hong Kong Stock Exchange, where 2359 trades as a stock.
• The trailing P/E ratio of 24.3 shows how much investors pay per unit of recent earnings; a lower P/E ratio can suggest a stock is cheaper relative to earnings, but comparisons within the same sector matter most.
• The forward P/E ratio of 20.2 uses expected future earnings, giving a sense of valuation based on what analysts anticipate.
• Earnings per share, trailing 12 months of 8.61 CNY represents the portion of net income attributable to each share over the past year.
• The dividend yield of 0.56% indicates the annual dividend as a percentage of the share price; this dividend yield is modest, reflecting that only 21% of earnings are paid out as dividends.
• Beta of 0.49 suggests the stock has historically been less volatile than the broader market, with a beta below 1.0 typically meaning lower sensitivity to market swings.
• Market capitalization of 636.12 mld. HKD reflects the total market value of all outstanding shares.
• Revenue, trailing 12 months of 51.52 mld. CNY shows the scale of the business over the last twelve months.

What to watch

Investors tracking WuXi AppTec often monitor the broader healthcare and diagnostics landscape, including peers such as WuXi Biologics (2269) and Hansoh Pharmaceutical Group (3692), which operate in related segments on the Hong Kong Stock Exchange. The nextEarningsDate of 22 oct. 2026 is a key date for updated financial results. Regulatory changes in drug development, pricing policies, and international trade dynamics can affect companies in this industry. The stock's price change over the last 52 weeks of 90.9% and its 52-week range of 96.7 – 212.8 illustrate the recent price trajectory and volatility envelope.